PTC-209

• CAT Number: I003125
• CAS Number: 315704-66-6
• Molecular Formula: C₁₇H₁₃Br₂N₅OS
• Molecular Weight: 495.19
• Purity: ≥95%
• Synonyms: N-(2,6-dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)-2-thiazolamine
• Target: Autophagy
• Solubility: DMSO: ≥ 32 mg/mL
• Storage: -20°C
• IC50: 0.5 uM
• IUPAC Name: N-(2,6-dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)-1,3-thiazol-2-amine
• InChI: InChI=1S/C17H13Br2N5OS/c1-9-15(24-5-3-4-20-16(24)21-9)13-8-26-17(22-13)23-14-11(18)6-10(25-2)7-12(14)19/h3-8H,1-2H3,(H,22,23)
• InChIKey: XVOOCQSWCCRVDY-UHFFFAOYSA-N
• SMILES: CC1=C(N2C=CC=NC2=N1)C3=CSC(=N3)NC4=C(C=C(C=C4Br)OC)Br

PTC-209（Cat No.:I003125）is a small molecule inhibitor that targets the RNA-binding protein Tob1, which plays a role in regulating gene expression and cell proliferation. It has shown potential in the treatment of certain cancers and neurodegenerative diseases, including Huntington’s disease. PTC-209 works by selectively inhibiting the function of Tob1, leading to alterations in cell cycle progression and apoptosis in cancer cells. Research suggests that it may be effective in reducing tumor growth, particularly in cancers resistant to conventional therapies. Ongoing studies are evaluating its therapeutic efficacy, safety, and potential as a cancer treatment.